INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Paper

Comparison of Medicinally Important Natural Products Versus Synthetic Drugs

Akash Nalawade*, Bhagyashri Chaudhari

Shivajirao S. Jondhle College of Pharmacy.

ARTICLE INFO

Published: 10 Aug 2026
Keywords:
Natural products, Synthetic drugs, Pharmacognosy, Drug design, Medicinal chemistry, Bioavailability, Nanomedicine, Pharmacoeconomics, Sustainability
DOI:
10.5281/zenodo.21871365

ABSTRACT

Medicinally valuable natural products and synthetic drugs are two pillars of pharmacotherapy. Natural products, derived from plants, microorganisms, marine organisms, and animals, have characteristic structural diversity and intrinsic biological activities that have defined the design of millions of therapeutic agents. Contrarily, synthetic drugs are rationally designed and optimized via chemical synthesis and have the advantages of reproducibility, specificity of action, and pharmacokinetics.This review will provide a fully comprehensive comparison of these two drug classes in terms of their origin, chemistry, mechanisms, pharmacological activity, benefits, limitations, and clinical use, and will aim to draw attention to advances made in the field from 2020 to 2025 that are ongoing or near-term developments such as drug design via AI, nanotechnology-based drug delivery, and green manufacturing processes. Figures and tables highlight quantitative differences, while real-life examples demonstrate the key contributions of natural and synthetic drugs to global health

INTRODUCTION

Nature has been humankind's best pharmacy ever since the dawn of time. From ancient medicinal plants to advanced today's formulations, natural molecules have dictated the path of medicine. More than 60% of the drugs in use today owe their origin to nature directly or through the process of semi-synthetic alteration [1].The dawn of synthetic chemistry during the 19th century transformed pharmacology by making possible the manufacture of reproducible, stable, and highly efficacious drugs. Synthetic drugs such as aspirin, barbiturates, and sulfonamides ushered in an age of specific pharmacotherapy. Increasing knowledge of side effects, resistance, and ecologically sustainable use, however, has created renewed interest in natural sources of drugs [2].
This review critically compares medicinally valuable natural products and synthetic drugs.1. It

***Corresponding Author:** Akash Nalawade
Address: *Shivajirao S.Jondhle College of Pharmacy*
Email ✉: akashnalawade2130@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

aims to (i) review their chemical and pharmacological differences, (ii) highlight clinical use and examples of therapy, (iii) contrast their pros and cons, and (iv) examine modern examples that integrate both paradigms, such as AI, green chemistry, and hybrid drug design.

2. A Historical Timeline of Drug Discovery

The historical timeline of drug discovery proceeds through three great periods: empirical era, synthetic era, and technological era.

2.1 Empirical Era (Before 1900).

In the empirical era, medicinal plants and animal-derived substances were the standard practices of the time. This period was based on therapeutic chemistry developed from crude extracts from opium (source of morphine), cinchona bark (source of quinine), and foxglove (source of digitalis) [3]. As an example, Ayurveda and Traditional Chinese medicine are examples of customary systems with polyherbal formulas still practiced today.

2.2 Synthetic Era (1900- 2000).

With the advances in organic chemistry and analytical chemistry, the ability to manufacture synthetic drugs was possible on a large scale. Bayer's synthesis of aspirin (acetylsalicylic acid) from the salicin in willow bark is an example of converting natural products into a chemically manufactured product. This time frame also includes penicillin derivatives, chlorpromazine, and beta-
blockers [4].

2.3 Technological and Post-Genomic Era (2000-present).

The simultaneous invention of bioinformatics, molecular modeling, and artificial intelligence has rapidly transformed drug discovery. Today, the use of high throughput screening and computer chemistry increasingly enhanced the speed of lead identification of natural products and synthetic drugs [5
[5]. Semi-synthetic drugs—chemical derivatives of natural products—have closed the gap between classical pharmacognosy and current medicinal chemistry.

3. Natural Products: Sources and Significance

Natural products, or secondary metabolites, are organic molecules yielded by living organisms that frequently have ecological roles such as defense, signaling, or competition. Their pharmacological significance is attributed to structural complexity, stereochemical diversity, and bioactivity.

3.1 Important Sources

- Plants: Alkaloids (morphine, vincristine), terpenoids (artemisinin, Taxol), and flavonoids (quercetin).
- Microorganisms: Antibiotics penicillin, streptomycin, and erythromycin.
- Marine organisms: Spong statin and bryostatin, exhibiting anticancer and antiviral activities.
- Animals: Peptides such as ziconotide (cone snail), appliedto neuropathic pain treatment [6].

3.2 Contribution to Contemporary Medicine

Over 35% of anticancer agents and 50% of anti-infective agents have been approved since 1980 and are derived from natural compounds [7]. They are also used as templates for semi-synthetic manipulation to make them more soluble, stable, and specific.

4. Synthetic Drugs: Design and Mechanistic Development

Synthetic medicines are chemically constructed molecules that act on biological targets to elicit

therapeutic action. They are designed by using Structure–Activity Relationships (SAR), Quantitative SAR (QSAR), and molecular docking methods.

4.1 Key Features

- High receptor or enzyme selectivity.
- Consistent pharmacokinetic profiles.
- Low-cost, scalable manufacturing.
- Enhanced shelf life and stability.

4.2 Mechanistic Breakthroughs

Artificial intelligence-based drug discovery platforms (e.g., AlphaFold, DeepDock) make 3D protein-ligand predictions, decreasing trial time [8].

Example: the structure of Atorvastatin, a man-made statin based on natural lovastatin, that emerged as the world's best-selling cholesterol medication.

5. Chemical Structure and Biosynthesis of Natural Products

Natural products are divided into primary metabolites (growth essential, e.g., amino acids, carbohydrates) and secondary metabolites (non-essential but bioactive, e.g., alkaloids, terpenoids, flavonoids). Such molecules exhibit vast stereochemical diversity that synthetic chemistry frequently fails to imitate[9].

5.1 Biosynthetic Pathways

- Polyketide Pathway: Synthesizes macrolides such as erythromycin.
- Shikimate Pathway: The pathway synthesizes aromatic compounds such as flavonoids and alkaloids.
- Mevalonate Pathway: Terpenes and steroids are derived from the pathway.
- Non ribosomal Peptide Synthesis (NRPS): Forms complex peptides such as vancomycin [10].
- Industrial metabolic engineering and synthetic biology strategies have maximized yields of naturally sourced drugs such as artemisinin, industrialized through engineered yeast strains [11].

5.2 Structural Diversity and Drug Likeness

- Natural products have "privileged structures," which feature numerous chiral centers, fused ring systems, and heteroatoms that improve receptor binding [12].
- Examples:
- Paclitaxel (Taxol): Diterpenoid from Taxus brevifolia, used in breast and ovarian cancers.
- Camptothecin: Alkaloid template for topoisomerase inhibitors such as irinotecan.
- Resveratrol: Polyphenol with antioxidant and cardio protective activity.
- These scaffolds provide inspiration for synthetic analogues possessing improved pharmacokinetics and safety.

6. Pharmacological Mechanisms of Synthetic Drugs

- Synthetic drug design follows molecular targeting principles of blocking, activating, or modulating particular receptors or enzymes.
- Some of the main strategies are:
- Receptor Agonism/Antagonism: e.g., β-blockers such as propranolol block β-adrenergic receptors.
- Enzyme Inhibition: e.g., NSAIDs block cyclooxygenase (COX) enzymes to suppress inflammation.
- Ion Channel Modulation: e.g., calcium channel blockers such as amlodipine reduce blood pressure.

6.1 Rational Drug Design

- Computational chemistry facilitates in silico screening of millions of chemicals with the help of AI-based software such as DeepChem, AutoDock Vina, and Open Pharmacophore [13].
- Recent examples (2020–2025) are:

- Molnupiravir, an antiviral drug against SARS-CoV-2, synthesized.
- Lasmiditan, a serotonin receptor agonist selective for migraine relief [14].

7.1 Natural Drugs' Inspirational Therapeutic Benefits

- Variety in chemical structures and scaffolding: Natural compounds typically have multiple chiral centers that can aid their binding and enhance biological activity [15].
- Fewer adverse effects: Many plant-derived drugs show significantly lesser toxicity or adverse reactions when compared to synthetic versions (e.g., curcumin vs. NSAIDs).
- Biocompatibility: Natural drugs come from biological origins, so they often have good bioavailability and metabolizm.
- Cultural and therapeutic acceptability: Used in traditional medicine systems worldwide.
- Scaffolding for innovation: Serve as templates for semi-synthetic adaptions.

7.2 Inadequate Therapeutic Benefits of Natural Drugs

- Variability in individual clinical response: Stability of potency can be influenced by geography, seasonality, and environmental factors.
- Difficulty in isolation and posology effects or benefits.
- Contamination with pesticides, microbes, or heavy metals.
- Limited shelf life and stability.
- Delayed effect due to complex mixtures and lower concentration of active compounds.

3. Advantages of Synthetic Drugs

- Consistency and purity: Each batch is identical in quality [16].
- Rapid therapeutic onset due to designed action.
- Simple mass production.
- Patented and thus cost effective.
- Possibilityof modifying pharmacokinetics via prodrug or salt formulation strategies.

4. Disadvantages of Synthetic Drugs

- Toxic side effects: E.g. paracetamol at toxic levels causes hepatotoxicity.
- Drug resistant strains: Over prescription of synthetic antibiotics has led to microbial resistance [17].
- Appointment of drugs produces waste leadingto environmental pollution.

Table 1. Comparison of Natural and Synthetic Drugs

Parameter	Natural Products	Synthetic Drugs
Source	Plants, microbes, marine life	Laboratory synthesis
Purity	Variable	High
Mechanism	Multi-target	Single-target
Toxicity	Generally lower	Can be high
Cost	Extraction-dependent	Scalable and predictable
Stability	Sensitive to environment	Chemically stable
Examples	Morphine, Artemisinin, Paclitaxel	Paracetamol, Atorvastatin, Ibuprofen

Figure 2: Bar Chart – Disease Categories Treated by Natural vs Synthetic Drugs

Category	Natural Drugs	Synthetic Drugs
Cancer	28%	35%
Infectious Diseases	40%	30%
Cardiovascular	10%	25%
CNS Disorders	12%	10%
Others	10%	–

3: Flow Schematic – From Discovery to Drug Market

- Natural Drugs: Collection → Extraction → Screening → Isolation →

Clinical Trials → Commercialization.

- Synthetic Drugs: Computational Design → Synthesis → Optimization

→ Preclinical & Clinical Trials → Market.

8. Application of Medicinally Important Natural and Synthetic Drugs

Natural products derived from plants as well as synthetic drugs form the basis for most therapeutic classes presently in use. Applications of both natural products and synthetic drugs range over topics including oncology, infectious disease, cardiovascular disease, neurologic disease, metabolic syndrome, and inflammatory disease.

8.1 Applications of Natural Medicinal Products

8.1.1 Anticancer Agents

Natural products have contributed a substantial number of anticancer agents.

- Paclitaxel (Taxol): Natural product extracted from the bark of Taxus brevifolia (Pacific yew) that stabilizes microtubules and prevents metaphase cell division in susceptible cancer cells. Taxol is still used presently as a first line therapy in treatments for ovarian/breast/lung cancer [18].
- Vincristine and Vinblastine: Natural product alkaloids derived from

Catharanthus roseus (Madagascar periwinkle) that inhibit microtubule formation for use in leukemia and Hodgkin's lymphoma treatment.

- Camptothecin: Natural product alkaloid commonly used to produce semi-synthetic derivatives, such as irinotecan and topotecan, which both inhibit topoisomerase I, which ultimately leads to cell death of susceptible cancer cells [19].

8.1.2 Antimalarial and Anti-infective Agents

Artemisinin: Sesquiterpene lactone derived from the plant Artemisia annua, camel's foot that produces reactive oxygen radicals, which leads to destruction of Plasmodium parasites [20].

Quinine: Alkaloid derived from the bark of Cinchona and still considered effective against P. falciparum malaria.

Berberine: Isoquinoline alkaloid from Berberis spp., which has broad spectrum antimicrobial and anti-diarrheal beneficial effects.

8.1.3 Cardioprotective and Anti-inflammatory Agents

- Resveratrol: A grape-derived polyphenol which activates sirtuin pathways enhancing endothelial function and reducing oxidative stress [21].
- Curcumin: A polyphenolic pigment from Curcuma longa with anti- inflammatory and

antioxidant activity, investigated extensively in metabolic and neurodegenerative diseases.

- Digitalis glycosides: From Digitalis purpurea, improved myocardial

contractility in heart failure.

8.1.4 Neuroprotective and Antidepressant Agents

- Ginkgo biloba extracts are associated with enhanced cerebral blood flow and have been reported to have neuroprotective properties in dementia.
- St John's wort (Hypericum perforatum): A serotonin reuptake inhibitor for mild depression [22].

8.2 Applications of Synthetic Drugs

8.2.1 Cardiovascular Agents

- Atorvastatin: A synthetic statin that inhibits HMG-CoA reductase, reducing cholesterol levels.
- Losartan: Angiotensin II receptor blocker for hypertension.
- Clopidogrel: A thienopyridine that inhibits platelet aggregation [23].

8.2.2 Antimicrobials and Antivirals

- Ciprofloxacin: A fluoroquinolone antibiotic inhibits DNA gyrase in bacteria.
- Azithromycin: A semi-synthetic macrolide derived from erythromycin with better acid stability and tissue penetration.
- Molnupiravir: A novel synthetic antiviral that targets SARS-CoV-2 RNA replication [24].

8.2.3 Analgesics and Antiinflammatories

- Paracetamol: A well-studied analgesic and antipyretic that is safe at therapeutic doses.
- Ibuprofen and Diclofenac: Synthetic NSAIDs that inhibit COX-1 and COX-2 to reduce prostaglandin synthesis.

8.2.4 Neuropsychiatric Drugs

- Fluoxetine: A selective serotonin reuptake inhibitor (SSRI) used for depression and anxiety.
- Diazepam: Benzodiazepine acting on GABA receptors to induce anxiolytic and sedative effects [25].

Figure 4: Bar Chart – Major Therapeutic Areas

Therapeutic Area	Natural Product Examples	Synthetic Drug Examples
Cancer	Paclitaxel, Vincristine	Imatinib, Tamoxifen
Cardiovascular	Digitalis, Resveratrol	Atorvastatin,
		Losartan
Infectious Diseases	Artemisinin, Quinine	Azithromycin, Ciprofloxacin
CNS Disorders	Ginkgo, St John’s wort	Fluoxetine, Diazepam
Diabetes	Gymnema sylvestre extract	Metformin

8.2.5 Anticancer and Antidiabetic Medications

Imatinib: A synthetic tyrosine kinase inhibitor that targets the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Metformin: A drug that belongs to the biguanide class of medications and that increases insulin sensitivity and glucose uptake.

8.3 Comparative Clinical Significance

Natural products have generally led the discovery of first-in-class drugs while some of the major forms of follow-on innovations are favored towards synthetic analogs .

For examples:-

A natural product like paclitaxel provided inspiration for docetaxel (semi- synthetic) with improved solubility.

A natural product like morphine provided inspiration for synthetic opioid products like fentanyl, much more potent but inherently riskier.

A natural product like lovastatin provided inspiration for synthetic statins like atorvastatin and rosuvastatin, with various safety and efficacies.

8.5 Inclusive Framework of Natural and Synthetic Methodologies

Recent pharmaceutical research has created a greater flow between the disciplines of "natural' and "synthetic" methodologies, producing formulations that integrate both natural and pure synthetic drug development.

A hybrid or semi-synthetic example is docetaxel (from paclitaxel) and semi- synthetic amoxicillin (with penicillin), or etoposide (from the natural molecule podophyllotoxin).

Artificial intelligence and high-throughput bioassays have also contributed to delineating which natural molecules can be ultimately optimized chemically, improving the capacity for efficacy and safety [26].

9.1 Pharmacokinetics and Bioavailability

The pharmacokinetics (ADME: Absorption, Distribution, Metabolism, and Excretion) assists in determining the extent of how effective a drug can reach its site of action. Natural products have poor solubility, low stability, and inconsistent absorption characteristics, which hampers their clinical effectiveness [27]. For Example; Curcumin has a strong potential as an anti-inflammatory, but has very poor oral bioavailability. Paclitaxel requires solvent-based formulations (i.e. Cremophor EL) for injections, which can cause anaphylactic events. There is potential for improvement of these challenges into newer approaches including; encapsulation into nanoparticles, liposomal carriers, and prodrug strategies, all assisting with solubility and systemic absorption [28]. Synthetic drugs are designed and modified as chemically stable products to allow for improved absorption. Synthesized prodrugs (enalapril → enalaprilat) are designed to improve oral bioavailability and decrease toxicity. Computational pharmacokinetic modeling now allow us to derive half-life, volume of distribution, and clearance values, thus reducing time in the drug development process [29]

9.2 Pharmacodynamics and Mechanism of Action

Natural drugs often act on multiple, non-specific targets, allowing us to exploit broader therapeutic effects with the trade off of difficulty elucidating the mechanism of action. Conversely, synthetic drugs are modified to have high affinity binding to specific drug targets, which allows for predictability and reproducible outcomes. For example; artemisinin acts through the generation of free-radicals within malaria parasites, while atorvastatin selectively inhibits HMG-CoA reductase to block cholesterol synthesis [30]. The advent of network pharmocology and multi-omics technologies (genomics, proteomics, metabolomics) allow us to holistically investigate the effects of natural compounds at the system-level [31].

9.3 Toxicity and Safety

The misconception that "natural equals safe" is widespread. Some plant- derived compounds (e.g., aconitine, ricin) are lethally toxic [32]. Synthetic drugs are tested rigorously, yet adverse drug reactions (ADRs) remain a leading cause of hospitalizations worldwide [33].

Type	Example	Toxicity Mechanism
Natural	Aconitine	Cardiotoxic via sodium channel activation
Natural	Pyrrolizidine alkaloids	Hepatotoxic via DNA adduct formation
Synthetic	Paracetamol	Hepatic necrosis in overdose
Synthetic	Cisplatin	Nephrotoxicity and ototoxicity

10. Technological Innovations: AI, Nanomedicine, and Hybrid Drug Design

10.1 Artificial Intelligence in Drug Discovery

- AI systems are increasingly screening millions of chemical entities in silico to predict both binding affinities and toxicity with impressive accuracy.
- DeepMind's AlphaFold (2021–2024) has transformed protein structure prediction, which will facilitate model research in drug-target interaction [35].
- BenevolentAI and Insilico Medicine have used machine learning to generate new synthetic analogs of existing natural scaffolds [36].
- These tools have simplified the development pipeline and will reduce costs and time with some classes of drugs from 10 years to under 4 years.

10.2 Nanomedicine for Drug Delivery

- Nanotechnology will promote the delivery of both natural and synthetic drugs by increasing target specificity and bioavailability.
- For example, nano-curcumin and liposomal doxorubicin have improved cancer therapies with fewer side effects.
- For poorly soluble drugs, solid lipid nanoparticles (SLNs) and polymeric micelles allow controlled release [37].

10.3 Hybrid and Semi-Synthetic Drugs

- Through semi-synthetic derivatization, the distinction between "natural" and "synthetic" is becoming increasingly blurred.
- Docetaxel is a semi-synthetic derivative of paclitaxel with a better pharmacological profile.
- Amoxicillin is a semi-synthetic derivative of penicillin resistant to acid degradation.
- Etoposide is a semi-synthetic derivative of podophyllotoxin with better oral availability [38].

11. Environmental Sustainability and Green Chemistry

- Concerns around sustainability in drug production is an emerging ethical and environmental concern.
- The overharvesting of medicinal plants threatens biological diversity, synthetic chemical processes (which require significant solvents and produce toxic by-products and waste) threaten human and environmental health.
- Green chemistry aims for the recognition of atoms in synthesis, to reduce the waste that we produce, and to seek out biodegradable solvents in

our work, renewable feedstocks and bio-processes [39].

- In synthetic biology, we can produce natural compounds (for example, artemisinin and morphine) responsible for medicinal benefits from microbial hosts, which reduces the ecological impact of products [40].
- The pharmaceutical industries are committing to LCA frameworks to assess the environmental footprint of medicine production; in both natural products and synthetic chemicals and medicines [41].

DISCUSSION

Natural and synthetic drugs should be viewed as a continuum, not a competition. Natural products possess unparalleled biological relevance and structural diversity, whereas synthetic chemistry provides specificity and scalability. Recent movement toward integrative approaches—using artificial intelligence (AI), synthetic biology, and green chemistry to merge natural and synthetic methods together—has captured the best of both worlds. Examples of integrative approaches include semi-synthetic drugs and hybrid drugs; both provide opportunities to integrate nature's creativity with human ingenuity, in adapting to the challenges we face.Nonetheless, we still face numerous challenges to our goals: developing standardized formulations of bioactive natural products, producing environmentally sustainable drugs, creating equitable intellectual property policies and access to novel biotechnologies.

Looking to the future, the focus on interdisciplinary approaches—global pharmognosy, medicinal chemistry, data science and ethics—will be key to developing new therapeutics that are both effective, sustainable, and safe.

CONCLUSION

Natural and synthetic drugs have distinct roles but contraindicate concerns in modern healthcare. For example, natural products are a well-documented source of novel pharmacophores and maintain templates for life-saving therapeutics, while synthetic chemistry allows for molecular design and optimization, cost-effective approaches, and national and global dissemination of natural products as drugs.

Computational artificial intelligence, nanotechnology, and environmentally sustainable chemistries, will establish the basis for the next generation of drug development where human safety, therapeutic efficacy, and environmental accountability will co-exist. The integration of natural and synthetic approaches will be essential to address contemporary demand for novel therapeutics that are also accessible and environmentally sustainable.

REFERENCES

1. D. J. Newman and G. M. Cragg, “Natural Products as Sources of New Drugs: 1981–2023 Update,” Journal of Natural Products, vol. 87, no. 3, pp. 112–154, 2023.
2. A. L. Harvey, “Trends in Natural Product Drug Discovery,” Drug Discovery Today, vol. 29, no. 4, pp. 101–118, 2024.
3. P. J. Houghton, Herbal Medicinal Products: Practical and Clinical Aspects, Springer, 2021.
4. . S. Lam et al., “A Renaissance in Antibiotic Discovery from Actinomycetes,” Current Opinion in Microbiology, vol. 72, pp. 102–114, 2023.
5. J. S. Graham et al., “Integrating AI and Chemical Informatics in Modern Drug Discovery,” Nature Reviews Drug Discovery, vol. 23, pp. 142–165, 2024.

6. R. P. Tiwari and M. Singh, "Marine-Derived Peptides and their Therapeutic Potential," Frontiers in Pharmacology, vol. 14, pp. 2223–2235, 2023.
7. P. Dewick, Medicinal Natural Products: A Biosynthetic Approach, 4th ed., Wiley, 2022.
8. S. N. Kapoor and R. Bansal, "Machine Learning-Assisted Drug Design," Molecules, vol. 28, pp. 117–137, 2023.
9. S. Mukherjee et al., "Synthetic Biology Approaches for Natural Product Derivatives," Biotechnology Advances, vol. 61, pp. 110–126, 2024.
10. M. Hughes et al., "Modern Principles of Drug Design," British Journal of Pharmacology, vol. 179, pp. 230–245, 2022.
11. G. Schneider, "Artificial Intelligence in Medicinal Chemistry," Nature Reviews Drug Discovery, vol. 22, pp. 97–113, 2023.
12. A. Patel and K. Mehta, "Biosynthetic Pathways of Plant Secondary Metabolites," Phytochemistry Reviews, vol. 22, pp. 477–491, 2023.
13. E. Feng and J. Wang, "Computational Screening and Docking Studies for Drug Discovery," Computational Biology and Chemistry, vol. 97, pp. 107–119,024.
14. S. R. Park et al., "Clinical Applications of Synthetic Small Molecules," Clinical Pharmacology & Therapeutics, vol. 115, pp. 22–34, 2023.
15. R. Bhattacharya, "Polyherbal Synergy in Modern Therapeutics," Frontiers in Pharmacology, vol. 14, pp. 1198–1214, 2023.
16. N. Patel et al., "Standardization Challenges in Herbal Medicine," Phytochemical Reviews, vol. 21, pp. 445–462, 2022.
17. D. Prasad et al., "Antimicrobial Resistance in Synthetic Drug Therapy," Lancet Microbe, vol. 5, pp. 210–223, 2024.
18. L. Xu and Z. Wang, "Paclitaxel: Biosynthesis and Clinical Updates," Cancer Letters, vol. 582, pp. 13–28, 2024.
19. V. Shukla et al., "Camptothecin and Its Derivatives: Progress and Prospects," Bioorganic & Medicinal Chemistry, vol. 78, pp. 117–132, 2024.
20. Y. Zhang et al., "Artemisinin-Based Combination Therapies," Trends in Parasitology, vol. 39, no. 2, pp. 84–98, 2023.
21. C. Lee and A. Banerjee, "Resveratrol and Cardioprotection: Recent Advances," Nutrients, vol. 16, no. 2, pp. 445–465, 2024.
22. J. Kim et al., "Herbal Neuroprotective Agents in CNS Disorders," Frontiers in Neuroscience, vol. 17, pp. 1052–1071, 2023.
23. . Nguyen et al., "Advances in Antiplatelet Therapy," European Journal of Pharmacology, vol. 941, pp. 175–196, 2023.
24. A. Kumar et al., "Synthetic Antiviral Drug Development," Antiviral search, vol. 220, pp. 105–126, 2024.
25. M. Li and J. Chen, "Psychotropic Drug Mechanisms and Safety," Journal of Clinical Psychiatry, vol. 84, pp. 122–138, 2023.
26. P. Choudhury et al., "AI-Assisted Natural Product Optimization," Computational and Structural Biotechnology Journal, vol. 21, pp. 2450–2463, 2023.
27. H. Rang and M. Dale, Pharmacology, 10th ed., Elsevier, 2022.
28. M. M. Yallapu et al., "Nanocarriers for Natural Product Delivery," Molecular Pharmaceutics, vol. 20, no. 3, pp. 675–692, 2023.
29. C. Li et al., "Prodrug Design and ADME Optimization," European Journal of Medicinal Chemistry, vol. 254, pp. 115–139, 2024.
30. A. Singh et al., "Comparative Pharmacodynamics of Natural and Synthetic

Drugs," Frontiers in Pharmacology, vol. 15, pp. 443–461, 2024.
31. A. Johnson et al., "Network Pharmacology and Multi-Omics in Drug Design," Nature Reviews Genetics, vol. 23, pp. 220–234, 2022.
32. P. Teschke and A. Eickhoff, "Hepatotoxic Risks of Herbal Drugs," Frontiers in Pharmacology, vol. 12, pp. 1105–1122, 2021.
33. . Walker and J. Green, "Global Burden of Adverse Drug Reactions," BMJ Global Health, vol. 9, no. 1, pp. 223–237, 2024.
34. J. Patel et al., "Toxicogenomic in Personalized Medicine," Pharmacogenomics Journal, vol. 24, pp. 85–102, 2024.
35. D. Jumper et al., "Highly Accurate Protein Structure Prediction with AlphaFold," Nature, vol. 596, pp. 583–589, 2021.
36. M. Zhavoronkov, "Generative AI in Pharmaceutical Discovery," Nature Biotechnology, vol. 42, pp. 324–340, 2024.
37. S. Alam et al., "Nanomedicine Applications for Drug Delivery," Advanced Drug Delivery Reviews, vol. 200, pp. 113–133, 2023.
38. T. Singh et al., "Semi-Synthetic Derivatives in Modern Drug Development," Medicinal Research Reviews, vol. 4pp. 54–78, 2024.
39. R. A. Sheldon, "Green Chemistry and Sustainable Synthesis," Green Chemistry, vol. 25, pp. 310–328, 2023.
40. J. D. Keasling et al., "Synthetic Biology for Sustainable Natural Product Production," Science, vol. 382, pp. 450–458, 2023.
41. IQVIA Institute, Global Pharmaceutical Market Report 2024, New York, 2024..

HOW TO CITE: Akash Nalawade, Bhagyashri Chaudhari, Comparison of Medicinally Important Natural Products Versus Synthetic Drugs, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 8, 1709-1719, https://doi.org/10.5281/zenodo.21871365